PROOF THAT YOUR FLU SHOT WILL TURN YOU INTO A CYBORG
$9.3 million award to boost nanotech vaccine research
Michigan Nanotechnology Institute and NanoBio Corporation to work in tandem to test nanoemulsion-based vaccines against common diseases
ANN ARBOR, Mich. - University of Michigan efforts to develop new nanoemulsion-based vaccines for a variety of diseases will move forward much more
quickly thanks to a large federal award.
The National Institute of Allergy and Infectious Diseases has awarded U-M a contract for $9,340,522 over five years. Of that total, $5,224,548 will
fund research at the Michigan Nanotechnology Institute for Medicine and Biological Sciences at U-M (MNIMBS), and $4,115,974 will fund work at Ann
Arbor-based NanoBio Corporation, the institute’s research partner for the project.
"This contract allows us to develop the process to apply our nanoemulsion technology to almost any form of antigen. We believe this will facilitate a
number of new vaccines as well as improve existing vaccines," says James R. Baker Jr., M.D., the grant’s principal investigator, director of the
Michigan Nanotechnology Institute, and Ruth Dow Doan Professor of Internal Medicine at U-M. He is also founder and CEO of NanoBio Corporation, in
which he holds a financial interest.
A nanoemulsion vaccine consists of a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The nanoemulsion acts as an
adjuvant, an ingredient in most vaccines that enhances the immune response to the weakened or partial pathogen.
Nanoemulsions, a technology developed and patented by U-M and licensed to NanoBio Corporation, have proved to be effective adjuvants.
In a number of previous preclinical studies at U-M, nanoemulsion-based vaccines, which are given in the nose, proved non-toxic and produced strong
immunity against influenza, anthrax, smallpox, HIV and hepatitis B. NanoBio Corp. is currently conducting a Phase I clinical trial of a
nanoemulsion-based intranasal vaccine for influenza.
[edit on 4-12-2009 by neverknwo]